Axsome Therapeutics AXSM Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's stock issuance proceeds?
- Axsome Therapeutics (AXSM) reported stock issuance proceeds of $6.34M in Q1 2026.
- How has Axsome Therapeutics's stock issuance proceeds changed year-over-year?
- Axsome Therapeutics's stock issuance proceeds decreased by 67.7% year-over-year, from $19.65M to $6.34M.
- What is the long-term trend for Axsome Therapeutics's stock issuance proceeds?
- Over 4 years (2021 to 2025), Axsome Therapeutics's stock issuance proceeds has grown at a 73.8% compound annual growth rate (CAGR), from $7.44M to $67.9M.
- What does stock issuance proceeds mean?
- Cash received from selling company shares to investors or employees.
- How do you interpret stock issuance proceeds?
- An increase provides liquidity for operations but results in shareholder dilution; a decrease suggests reduced reliance on equity markets.
- How does stock issuance proceeds compare across companies?
- High for clinical-stage biotechs frequently accessing capital markets to fund R&D; lower for mature, cash-flow-positive firms.